Theravance THRX
-
GlaxoSmithKline: The Good News Just Keeps On Coming
By Cris Frangold : Just last month GlaxoSmithKline (NYSE: GSK ) was in the news for a move to acquire Human Genome Sciences (NASDAQ: HGSI ), its partner of up to twenty years for $2.6 billion. If you follow the news, you will remember that Human Genome Sciences rejected the offer saying that the ...
-
GlaxoSmithKline's Q1 Call Has Muted Mention Of Relovair
By Rocco Verducci : I would like to provide balance, as a preamble to my article, by stating that although there was nominal mention of Relovair in the actual transcript of the Q1 Earnings Call itself, the official press release of the Q1 results did contain several lines that addressed the ...
-
Theravance ( THRX ): Q1 EPS of $0.93 misses by $0.09. Revenue of $127.1M (+1917% Y/Y) beats by $16M. (PR)
Theravance ( THRX ): Q1 EPS of $0.93 misses by $0.09 . Revenue of $127.1M (+1917% Y/Y) beats by $16M . ( PR ) Post your comment!
-
Glaxo Posts Slightly Disappointing First-Quarter, but Pipeline Continues to Make Strides
… and a lack of superiority to Advair in some COPD and asthma studies), Glaxo nonetheless increased its ownership to 27% (from 18%) in Theravance (a partner on Relovair), which we believe shows Glaxo's confidence in the drug.
-
GSK ups lung drug bet by buying more of Theravance
LONDON (Reuters) - GlaxoSmithKline bet another $212.9 million on the success of lung drug Relovair on Monday by raising its stake in U.S. biotech firm Theravance - its partner on the new medicine -...
-
Theravance : Vote Of Confidence?
By Robert Broens : Shares of Theravance ( THRX ) gained 19% after GlaxoSmithKline ..... bought 10 million shares of Theravance for $21.29 a piece, thereby ..... good news for shareholders of Theravance . The company is able to raise …
-
GSK ups lung drug bet by buying more of Theravance
LONDON (Reuters) - GlaxoSmithKline bet another $212.9 million on the success of lung drug Relovair on Monday by raising its stake in U.S. biotech firm Theravance - its partner on the new medicine -...
-
GSK ups lung drug bet by buying more of Theravance
LONDON (Reuters) - GlaxoSmithKline has increased its stake in Theravance to 26.8 percent by buying shares worth $212.9 million at a premium to the market, in a move signaling its confidence in new...
-
4 Biotech Stocks With Strong Upside Potential
By Ry Frank : The last twelve months have been a rocky ride for Human Genome Sciences ( HGSI ) , once tipped as the bright young things of the Biotechnology industry. Since April 2011, shareholders have seen the value of Human Genome stocks fall from a healthy $30 to just under $8 per share, in a
-
10 Biotech Stocks Positively Correlated To Volatility
By Kapitall : Do you worry that the market will see significant volatility in the near future? One idea is to consider a stock's historical correlation to volatility - stocks that are positively correlated may have been treated as safe havens. To illustrate this, we ran a screen on the biotech ...